All In Biotech

Free tool

FAERS Monitor: Otulfi

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761379 or its brand name (Otulfi, Ustekinumab-Aauz). Reports on generic versions are filed under their own applications.

Reports

17

Serious

11

65% of reports

Hospitalization

4

Death reported

2

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • pain3
  • accidental exposure to product2
  • anxiety2
  • death2
  • drug ineffective2
  • eosinophilic oesophagitis2
  • exposure via skin contact2
  • fatigue2
  • product use in unapproved indication2
  • treatment failure2
  • abdominal discomfort1
  • acute kidney injury1
  • blindness1
  • blood chloride decreased1
  • blood sodium decreased1

Reports by year received

View as table
YearReports
20256
202611

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,142 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
eosinophilic oesophagitis2894.2243.11,002
blood chloride decreased1480.071.7119
exposure via skin contact295.526.0105
blood sodium decreased165.79.815
blindness130.44.57
treatment failure229.98.131
accidental exposure to product224.06.524
product use in unapproved indication210.02.79
anxiety28.72.47
acute kidney injury18.11.21
abdominal discomfort17.41.11
painSignal36.02.28
fatigue23.20.91
death22.90.81
drug ineffective21.90.50

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.